TY - JOUR
T1 - Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
AU - Fabbiani, Massimiliano
AU - Di Giambenedetto, Simona
AU - Quiros Roldan, E
AU - Latini, A
AU - Vullo, V
AU - Antinori, A
AU - Castagna, A
AU - Orofino, G
AU - Francisci, D
AU - Grilli, E
AU - Madeddu, G
AU - Grima, Pierfrancesco
AU - Rusconi, S
AU - Del Pin, B
AU - Mondi, Annalisa
AU - Borghetti, Alberto
AU - Focà, E
AU - Colafigli, Manuela
AU - De Luca, Andrea
AU - Cauda, Roberto
PY - 2014
Y1 - 2014
N2 - We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.
AB - We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.
KW - HIV
KW - simplification
KW - HIV
KW - simplification
UR - http://hdl.handle.net/10807/61166
U2 - 10.7448/IAS.17.4.19808
DO - 10.7448/IAS.17.4.19808
M3 - Conference article
SN - 1758-2652
VL - 17
SP - 19808
EP - 19808
JO - Journal of the International AIDS Society
JF - Journal of the International AIDS Society
T2 - HIV Drug Therapy Glasgow Congress 2014
Y2 - 2 November 2014 through 6 November 2014
ER -
